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Introduction
The ultimate role of B lymphocytes is to produce Igs, what necessitates their differentiation into plasma cells, as a result of a complex cascade of events which requires precise and coordinated regulation (1) (2) (3) . After antigen binding, naive B cells proliferate in a T cell-dependent fashion within the paracortical T cell-rich areas of secondary lymphoid organs. Then, a proportion of proliferating B cells mature into plasma blasts that will migrate to medullary cords to become plasma cells, while some B cells migrate into primary follicles to initiate the germinal center reaction. Germinal centers allow the generation of memory B cells and plasma blasts which have the potential of secreting antibodies of high affinity and high specificity. These plasma blasts migrate out of the follicles to colonize either the mucosal lamina propria, or the bone marrow (4, 5) where they terminally differentiate into high-rate Ig secreting plasma cells.
In some pathological circumstances, plasma cells are also found in ectopic sites. Indeed in RA, an accumulation of plasma cells has been demonstrated among the mononuclear cells infiltrating the synovium of affected joints (6) (7) (8) . The inflammatory synovial tissue was shown to share with normal lymphoid organs, structural and functional properties, including B cell and T cell-rich areas, the presence of dendritic cells and plasma cells, and an important Ig production (9, 10) . In RA synovitis, plasma cells are organized in clusters located in the transitional areas in close contact with macrophages, synoviocytes and blastic CD8' T cells, at the margin of the lymphocyte rich area mainly composed of small CD4' T cells aggregated around post-capillary venules with tall endothelium (11) . The mechanisms through which plasma cells accumulate in the synovium have not yet been explored. Therefore, we engaged into the study of the role of synovium microenvironment in B cell differentiation. To mimic in vitro the ectopic development of plasma cells, we assessed the capacity of purified rheumatoid synoviocyte cultures (12) , to 
Methods
Cytokines and cell lines. Each of the recombinant human cytokines from the following sources were used at the following concentrations, known to be saturating in various biological assays. IL-1f3 (1 ng/ml), LL-6 (40 ng/ml), and TNF-a (20 ng/ml) from Genzyme (Boston, MA); IL2 (10 ng/ml) and IFN-y (lOng/ml) from Amgen Biologicals (Thousands Oaks, CA); IL-3 (15 ng/ml), GM-CSF (100 ng/ml), IL-4 (5 ng/ml), and IL-10 (50 ng/ml) from the Schering-Plough Research Institute (Kenilworth, Antibodies. The monoclonal mouse antibodies used for the phenotypic studies were purchased from the following sources: FITC-conjugated anti-CD3 (IOT3), anti-CD19 (IOB4), anti-CD20 (IOB20), and anti-CD54 (ICAM-1) from Immunotech (Marseille, France); FITC-con-jugated anti-CD1O (Calla), anti-CD14 (Leu M3), anti-HLA-DR, phycoerythrin-conjugated anti-CD38 (Leu 17) from Becton Dickinson Monoclonal Center (Mountain View, CA); FITC-conjugated anti-CD44 (A3D8) from Sigma Chemical Co. (St. Louis, MO); and FITC-conjugated anti-CD28 from CLB (Amsterdam, The Netherlands). The anti-CD40 mAb 89 was produced in the laboratory as described previously (13) . The mouse anti-K and anti-A antibodies used for the immunoenzymatic staining were from Dako (Glostrup, Denmark). The anti-CD2 and anti-CD3 mAbs used for the negative selection of B cells with magnetic beads were purchased from Aster Laboratories (La Gaude, France).
Synoviocyte preparation. RA synoviocytes were isolated from synovial biopsies obtained from RA patients undergoing knee or wrist synovectomy. Normal synoviocytes were obtained from patients undergoing knee arthroscopy for traumatic ligament lesions. Synovia were finely minced and digested with 4 mg/ml collagenase (Worthington Biochem. Corp., Freehod, NJ) for 2-3 h at 370C. After centrifugation, cells were resuspended in complete a-MEM medium as detailed elsewhere (12) . After 48 h, non-adherent cells were removed. Adherent cells were cultured in complete medium, and at confluence were passaged in a 1:3 ratio after trypsin treatment. Synoviocytes were used between passages 3 and 8. They were a homogenous population of fibroblast-like cells, negative for the expression of CD3, CD19, CD14, and HLA-DR, and positive for the expression of CD44, CD10, and CD54, as determined by flow cytometry analysis.
B lymphocyte purification. Tonsillar mononuclear cells were separated by standard Ficoll-Hypaque gradient method and were submitted to rosetting with sheep red blood cells. Nonrosetting cells were next labeled with anti-CD2 and anti-CD3 mAbs, and subsequently incubated with magnetic beads coated with anti-mouse IgG antibodies (Dynal, Oslo, Norway). Residual non B cells were removed by applying a magnetic field. The purity of B cell population was routinely > 95%, as estimated by flow cytometry analysis using anti-CD19, CD20, CD3, and CD14 mAbs.
SAC blast preparation. SAC blasts were prepared as previously described (14) . Briefly, purified tonsillar B cells at 2 X 106 cells/ml in RPMI 1640 medium (GIBCO BRL, Grand Island, NY) supplemented with 10% FCS (GIBCO BRL), 2 mM glutamine, 100 U/ml penicillin, and 100 ug/ml streptomycin (all from IgG, IgM, and IgA levels were determined in supernatants by standard ELISA techniques, as described earlier (14) . For milliliter. Moreover, when IL-2 andIL-10 were used in combination a strong synergistic effect was observed, and the own effect of synoviocytes was dramatic since they enhanced by 13-884-fold the production of IgG (2.0±1.4 jig/ml without vs.
62.5±19.0,ug/ml with synoviocytes, n = 14, P <0.001). In the same supernatants, IgM levels were similarly affected by the cytokines but they were lower than those of IgG in each condition (data not shown). IL-5 was also tested in the same culture conditions and showed no effect on IgG, M and A production (data not shown).
The synergy between IL-2 and IL-10 on IgG production by B cells cocultured with synoviocytes and SAC was dose dependent (Fig. 3, A and B) . The maximal effect was obtained with 10-20 U/mI of IL-2 associated with 30-50 ng/ml of IL-E PLASTIC 10 Kinetic studies showed that IgG production by B cells cultured over synoviocytes started at day 6 (Fig. 3 C) (Fig. 7) . All these cells were also CD44' and CD10-as described for normal bone marrow plasma cells (16) . CD28 which had been observed on plasmacytoma cell lines (18) was not expressed on these cells. Synoviocytes promote B cell survival while stimulating their terminal differentiation toward high rate Ig-secreting plasma cells. We wondered whether the activity of synoviocytes to sustain B cell differentiation was related to an induction of B cell proliferation. SAC blasts were used to separate B cell growth due to SAC from that induced by synoviocytes. SAC Blasts were cultured either on plastic, MRC5 or synoviocytes, with IL-2 and IL-10. Viable B cell recovery was measured every third day in parallel with IgG levels. As shown in Fig. 8 B) between synoviocytes, MRC5 cells and plastic appears to be related to a different ability to support B cell survival. Furthermore, the production of IgG per cell between days 9 and 12 was 4.6-fold higher on synoviocytes (0.19 ng/cell per day,) than on MRC5 (0.04 ng/ cell per day).
To confirm these results, the expression of CD38 and CD20 was compared between B cells cocultured with synoviocytes or with MRC5. As presented in Fig. 9, A (27, 28) , which had so far been described as the most efficient conditions allowing B cell differentiation. It is also important to note that, unlike these two culture systems, the cocultures over synoviocytes suggest that differentiation of B cells can be induced in vitro in a CD40 independent fashion, since synoviocytes do not express surface GP-39, the ligand for CD40 (our unpublished results). This observation is in accordance with the increased production of IgM by patients with Xlinked Hyper-IgM syndrome, while their CD40-CD40-ligand interactions are abolished through point mutations in the CD40-ligand gene (29) (30) (31) .
Several other adherent fibroblast-like human cell lines were much less potent than synoviocytes to improve B cell differentiation. This particular property of synoviocytes to sustain the maturation of B cells into plasma cells was related to their ability to support B cell survival. Moreover, synoviocytes induced a more efficient differentiation of B cells since the levels of IgG produced per cell were 4.6-fold higher, and their CD38 expression was stronger, in cocultures performed with synoviocytes than with MRC5. It is difficult to precisely define the role of synoviocytes in the B cell terminal differentiation process, but it is clear that contact with synoviocytes cannot circumvent need for B cell activation signals and cytokines such as IL-2 and IL-1O. Preliminary results of two chamber culture systems, where B cells and synoviocytes were separated by a semi-permeable membrane, suggest that both direct cell contact and soluble factors are necessary for the differentiation to occur.
Although interaction between a4,61 integrin (also known as VLA-4) and Fibronectin has been shown earlier to play an important role in terminal B cell differentiation of total human bone marrow cells (32) , blocking anti-VLA-4 antibodies did not modify Ig production in cocultures of B cells with synoviocytes (data not shown). Further studies are now in progress to produce mouse monoclonal antibodies directed against synoviocyte membrane antigens, in order to further identify the molecules involved in the support of B cell differentiation into plasma cells through synoviocyte interaction.
The ability of synoviocytes to induce B cell differentiation was not related to their rheumatoid origin as normal synoviocytes possessed the same capacity. Since there is no plasma cells in normal synovium, these results lead to assume that the peculiar property of synoviocytes to induce terminal differentiation of B cells, is a necessary but not sufficient condition for plasma cells to accumulate in synovial membrane. The follow-d ing events, which take place in rheumatoid but not in normal synovium, are most likely required for plasma cell accumulation. (a) An initial immune response to a presently unknown antigen; (b) the infiltration of RA synovium by B cell-containing mononuclear cells; (c) the local production of IL-10 by infiltrating monocytes and T cells (33) ; (d) the local production of ILi 2 by infiltrating T cells (34) ; and (e) the intense proliferation of synoviocytes which may increase their interaction with B cells. Previous electron microscopic studies of rheumatoid synovium had demonstrated the close contact between plasma cells, macrophage-like cells, blastic T cells, and synoviocytes (11, 35) , which suggest cell surface molecule or cytokine interactions between all these cell types. Besides, several studies indicate that RA synovial tissue is a privileged site for specific B cell maturation. Analysis of synovial Vk transcripts has evidenced an oligoclonal expansion of B cells in a RA synovium, but neither in the PBL of the patient, nor in the spleen or PBL of normal individuals (36) . Moreover, studies of RA synovial IgG rheumatoid factors have also revealed somatic mutations characteristic of an antigen-driven immune response (37, 38 
